A Phase 2 Study - Clinical Trial Assessing Efficacy and Safety of the mTOR Inhibitor Sirolimus in the Treatment of Complicated Vascular Anomalies
Latest Information Update: 09 Jan 2026
At a glance
- Drugs Sirolimus (Primary)
- Indications Lymphatic disorders; Vascular disorders
- Focus Therapeutic Use
Most Recent Events
- 06 Jan 2026 Status changed from active, no longer recruiting to completed.
- 10 Feb 2016 New trial record
- 18 Jan 2016 Results published in the Pediatrics